Regeneron and Sanofi Present Positive Results of Libtayo (cemiplimab) from P-III Trial for Cervical Cancer at ESMO2021

 Regeneron and Sanofi Present Positive Results of Libtayo (cemiplimab) from P-III Trial for Cervical Cancer at ESMO2021

Shots:

  • The P-III trial involves assessing libtayo (300mg, IV, q3w) as monothx. vs CT in patients with recurrent or metastatic cervical cancer that has progressed on platinum-based CT. The companies expect the regulatory submission in 2021
  • The results demonstrated a 31% reduction in the risk of death in the total population, improvement in OS, PFS, and ORR (16% vs 6%), mDoR (16 mos. vs 7 mos.), and 25% reduction in the risk of disease progression
  • Libtayo is a fully human mAb targeting the immune checkpoint receptor PD-1 on T-cells. The use of Libtayo for advanced cervical cancer is investigational and has not been fully reviewed by any regulatory authority

Click here to­ read full press release/ article | Ref: Regeneron | Image: Regeneron

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post